Advertisement

Picture Berlin Partner Top News CRIPSR Repairs Immune Cells 650x100px
Document › Details

Novimmune S.A.. (1/4/17). "Press Release: Novimmune Grants Tiziana an Exclusive License to NI-1201, an anti-IL-6R Monoclonal Antibody for the Treatment of Autoimmune and Inflammatory Diseases". Geneva.

Organisations Organisation Novimmune S.A.
  Organisation 2 Tiziana Life Sciences plc (AIM: TILS, Nasdaq: TLSA)
Products Product NI-1201 (Novimmune / Tiziana)
  Product 2 foralumab (NI-0401)
Index term Index term Tiziana–Novimmune: therapeutic antibody, 201701– license excl €na to develop + commercialise anti-IL-6R MAb NI-1201
Persons Person Holdener, Eduard (Ed) (Novimmune 201512– CEO before Roche CMO)
  Person 2 Mills, Adrian (Novimmune 201409– CBO before GSK since 2000)
     


Novimmune, a Swiss biotech company focused on the discovery and development of antibody-based drugs, and Tiziana Life Sciences (TILS), have signed a second collaboration agreement granting Tiziana exclusive rights to develop and commercialize its anti-IL-6R monoclonal antibody, NI-1201.

Anti-IL6R antibodies are marketed or in development for a range of inflammatory conditions including rheumatoid arthritis. Tiziana intends to explore the development of NI-1201 in Non-alcoholic Steato hepatitis (NASH), diabetes and other life threatening inflammatory diseases, as well as foralumab (NI-0401), the first antibody that Novimmune licensed to Tiziana in December 2014. Financial details were not disclosed.

“Two years ago, we entered into our first collaboration with Tiziana and we have been very pleased with the progress they have made with NI-0401, currently in phase 2 clinical development. We are delighted to have signed this second agreement to move NI-1201 forward, and we believe this is a very exciting molecule which complements Tiziana’s portfolio.” said Novimmune Chairman and Chief Executive Officer, Eduard Holdener.


About Novimmune

Novimmune SA is a privately held, Swiss biopharmaceutical company focused on the discovery and development of antibody-based drugs for the targeted treatment of inflammatory diseases, immune-related disorders, and cancer. The company is headquartered in Geneva and currently employs 122 people. More information is available on the company website at www.novimmune.com.


Contact:

Adrian Mills
+41 (0) 61 201 13 27
amills@novimmune.com

   
Record changed: 2023-06-05

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Novimmune S.A.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x300px




» top